Raltegravir Not Better Than NRTIs for Refractory HIVRaltegravir Not Better Than NRTIs for Refractory HIV

Raltegravir showed no benefits over nucleoside reverse-transcriptase inhibitors when used in combination with a protease inhibitor as second-line HIV therapy. Medscape Medical News

Source: Medscape Medical News Headlines - July 23, 2014 Category: Consumer Health News Tags: HIV/AIDS News Source Type: news